Nov 8 (Reuters) - Y-mAbs Therapeutics Inc YMAB.O:
Y-MABS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND RECENT CORPORATE DEVELOPMENTS
Y-MABS THERAPEUTICS - REITERATES FULL YEAR 2024 GUIDANCE
Y-MABS THERAPEUTICS INC: QTRLY TOTAL NET REVENUE $18.5 MILLION
Y-MABS THERAPEUTICS INC: QTRLY NET LOSS PER SHARE $0.16
Source text: ID:nGNX4qDFPW
Further company coverage: YMAB.O
((Reuters.Briefs@thomsonreuters.com;))